AXT-1005

N/A

Report date: 2024/05/28 15:35:23
NME

Base Information

Drug NameAXT-1005
Drug Alias NameAXT-1005
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAstoc Biomedical (Tianjin) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstoc Biomedical (Tianjin) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A